Chronic
hepatitis B (CHB) remains a major public health problem
worldwide, with limited treatment options, but inducing an antiviral
response by innate immunity activation may provide a therapeutic alternative.
We assessed the cytokine-mediated anti-hepatitis B virus (HBV) potential
for stimulating the cyclic GMP–AMP synthase–stimulator
of interferon genes (STING) pathway using STING agonists in primary
human hepatocytes (PHH) and nonparenchymal liver cells (NPCs). The
natural STING agonist, 2′,3′-cyclic GMP–AMP,
the synthetic analogue 3′,3′-c-di(2′F,2′dAMP),
and its bis(pivaloyloxymethyl) prodrug had strong indirect cytokine-mediated
anti-HBV effects in PHH regardless of HBV genotype. Furthermore, STING
agonists induced anti-HBV cytokine secretion in vitro, in both human and mouse NPCs, and triggered hepatic T cell activation.
Cytokine secretion and lymphocyte activation were equally stimulated
in NPCs isolated from control and HBV-persistent mice. Therefore,
STING agonists modulate immune activation regardless of HBV persistence,
paving the way toward a CHB therapy.